NEAL VAN HOEVEN
Vice President, Preclinical Research @ Cabaletta Bio
About
• Builder and scientific leader of teams for innovative biotechnology companies. Capable of driving drug development across all pre-clinical and clinical stages. • Extensive experience and expertise in gene and cell therapy, specializing in gene delivery, vector design, manufacturing, regulatory and quality challenges, and vector-host biology. • Expert in vaccine development across a range of modalities including nucleic acid delivery, viral vectored, and adjuvanted protein antigens. • Experienced in animal model development, disease modeling, and therapeutic assessments in multiple animal species using both immunocompetent and humanized animal models. • Experienced in collaborating with CMO’s for product manufacturing and CRO’s for qualified assay development. • Experience in the authorship of regulatory and governance documents. • Proven track record of innovation with multiple patents and publications. Specialties: Vaccinology, gene therapy, animal models, viral vector design, production and purification, virology, biotechnology project management.
United States
Seattle
Biotechnology
Conference Presentations, Strategic Thinking, Multi-disciplinary Teams, Technology Trends, Research and Development (R&D), External Communications, Vendor Partnerships, Molecular Virology, Product Development, Cross-functional Team Leadership, Vaccines, Molecular Biology, Biotechnology, Animal Models, Assay Development, Clinical Development, Flow Cytometry, Animal Work, Molecular Cloning, Tissue Culture
Experience
Vice President, Preclinical Research
Cabaletta Bio
Phildelphia, PA
Owner and Principal Scientist
Van Hoeven Consulting LLC
Seattle Area
I maintain an independent consultancy specializing in infectious disease and gene therapy experimental design and execution. In this capacity, I have assisted several local biotechnology companies in executing preliminary proof of concept studies for small molecule therapeutics.
Senior Director: Viral Vector Discovery and Head of In Vivo Research for T-Cell Therapies
Sana Biotechnology, Inc.
Seattle, Washington, United States
Leading a multidisciplinary team of scientists and technicians across several functions (both in-vivo and in-vitro). Responsible for preclinical and IND enabling research across Sana's T-Cell therapeutics platform, including both viral and cell based therapeutic product candidates.
Director: Viral Vector Discovery
Sana Biotechnology, Inc.
Seattle, Washington, United States
Leading Efforts to enable a novel gene-therapy platform for treatment of a range of oncology indications.
Affiliate Assistant Professor
University of Washington Department of Global Health
Seattle, WA
Actively engaged in lectures and other activities as an adjunct professor. Current courses include lectures in globally significant infectious diseases (GH410) as well as short courses in vaccine development.
Senior Scientist
Access to Advanced Health Institute (AAHI), [Formerly Infectious Disease Research Institute]
Seattle
• Responsible for management of a multi-disciplinary team including up to 9 Ph.D. and non-Ph.D. direct reports carrying out research in both early discovery and late-stage product development activities for a novel replicon based RNA-based gene delivery platform as well as multiple protein-adjuvant and virus-vectored vaccine candidates. • Active Participant in institutional leadership meetings to set overall product development priorities, research strategies and define organization structure. • Maintained direct research and budgetary supervision of a DOD/DARPA funded gene delivery project with a duration of 5 years and a $2 million dollar annual budget. • Awarded (as Principal Investigator) a multi-year NIH development contract to carry a novel RNA-based Yellow Fever Virus vaccine through pre-clinical research and formal product development activities, culminating in a Phase I clinical trial. Responsible for all aspects of proposal development and project management. Total contract value: $17 Million USD.
Scientist II
Infectious Disease Research Institute
Seattle, WA
Research Scientist
Immune Design
Leader in the development of novel dendritic cell targeted viral vector platform for vaccine delivery.
Post-Doctoral Fellow
Centers for Disease Control and Prevention
Post-Doctoral Fellow, conducting research on H5N1 avian influenza virus. Research is focused on assessment of pandemic risk of these viruses as well as effectiveness of novel therapeutics.
Graduate Student
University of Washington
Graduate Student reasearcher. Studies focused on basic biology of mammalian retroviruses, with the goal of developing better viral vectors for gene therapy.
Education
University of Washington
Biotechnology Project Management
Completed a 1 year course in Biotechnology Project Management jointly taught by UW and UCSD. Course Completed in 2012.
University of Washington
Molecular Biology/Virology
Middlebury College
Molecular Biology and Biochemistry
NEAL VAN HOEVEN's Contact Information
Phone
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles
Find Emails
Access verified email addresses for your target contacts.
657M+ emails
Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers
More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.